Merck names Michael J. Holston as future General Counsel; Will succeed Bruce N. Kuhlik in July 2015
25 June 2014 | By Merck
Merck announced the future appointment of Michael J. Holston as general counsel, effective July 01, 2015...
List view / Grid view
News
Phase 3 first-line melanoma study of Nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to Dacarbazine; study stopped early
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early...
Abbott to acquire Veropharm
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
CEO and Chairman of UPS, D. Scott Davis, Joins Johnson & Johnson Board of Directors
23 June 2014 | By Johnson & Johnson
Johnson & Johnson announced that its Board of Directors has appointed D. Scott Davis, Chief Executive Officer and Chairman of United Parcel Service, Inc. as a Director of Johnson & Johnson...
Prevenar 13® Indication extended in Japan
23 June 2014 | By Pfizer
Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children...
Merck begins tender offer to acquire Idenix
23 June 2014 | By Merck
Merck is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
AbbVie declares quarterly dividend
23 June 2014 | By AbbVie
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $0.42 per share...
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
23 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation...
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
Janssen announces License Agreement with Vertex to develop novel treatment for influenza A
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals...
Brintellix® demonstrated a statistically significantly superior improvement compared to escitalopram in improving sexual functioning in well treated patients suffering from depression and experiencing treatment-emergent sexual dysfunction
19 June 2014 | By H. Lundbeck A/S
Lundbeck will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs. escitalopram in patients with well treated Major Depressive Disorder...
Teva reaches settlements in NUVIGIL® patent case
18 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that it has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7,132,570 for Teva’s wakefulness product, NUVIGIL® (armodafinil) tablet...
Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
